Every 10-Q that Zimmer Biomet (ZBH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBH filings page.
Zimmer Biomet Holdings, Inc. reported second‑quarter 2026 net sales of $2,177.0 million, up from $2,077.3 million a year earlier, and net earnings attributable to Zimmer Biomet of $198.3 million versus $152.8 million, with diluted EPS of $1.03 versus $0.77.
For the first six months, net sales were $4,263.7 million and net earnings attributable to Zimmer Biomet were $436.5 million compared with $3,986.4 million and $334.9 million. Net cash provided by operating activities reached $807.2 million, funding $349.8 million of investing outflows and $640.3 million of financing outflows including $500.8 million of share repurchases and $93.4 million of dividends.
Total assets were $22,797.8 million and cash and cash equivalents $410.0 million at June 30, 2026, with current and long‑term debt of $1,201.5 million and $6,277.5 million. The 2025 Restructuring Plan is expected to generate total pre‑tax charges of about $155.0 million, of which $146.5 million had been incurred, while recent Paragon 28 and Monogram acquisitions added goodwill and IPR&D in foot, ankle and robotics technologies.
Zimmer Biomet reported stronger results for the quarter ended March 31, 2026. Net sales rose to $2,086.7M, up 9.3% from $1,909.1M a year earlier, driven by the Paragon 28 acquisition, foreign currency tailwinds, customer stocking, ROSA robots, and new products.
Net earnings attributable to Zimmer Biomet increased to $238.1M from $182.0M, with diluted EPS rising to $1.22 from $0.91. Knees, Hips, S.E.T., and Technology & Data, Bone Cement and Surgical all grew, with S.E.T. up 19.5%.
Operating profit improved to $373.2M, supported by a roughly $30M benefit from probable U.S. tariff refunds, lower restructuring charges, reduced R&D spending, and restructuring savings. For 2026, the company expects net sales growth of 2.5%–4.5%, including contributions from Paragon 28 and modestly positive foreign exchange.
Zimmer Biomet (ZBH) reported third‑quarter results. Net sales were $2,001.4 million, up from $1,824.2 million. Operating profit rose to $351.3 million from $279.5 million, while net earnings attributable to the company were $230.9 million versus $249.1 million a year ago. Diluted EPS was $1.16 (prior year $1.23). By category, Q3 sales were Knees $792.4 million, Hips $506.2 million, S.E.T. $541.5 million, and Technology & Data, Bone Cement and Surgical $161.3 million.
For the first nine months, net sales reached $5,987.7 million with operating cash flow of $1,179.7 million. The balance sheet showed cash and cash equivalents of $1,292.7 million and long‑term debt of $7,512.6 million as of September 30, 2025. The company completed the Paragon 28 acquisition, paying $1,241.5 million in cash plus contingent consideration fair‑valued at $35.0 million, recording $635.6 million of goodwill. During 2025, Zimmer Biomet issued new senior notes (including $1,748.1 million in U.S. dollar notes and $744.0 million in Swiss Notes) and redeemed $863.0 million of 2025 notes. A quarterly dividend of $0.24 per share was declared.